益脾养肝方对肝癌前病变大鼠血清IL-6、TNF-α的影响

Effect of Yipi Yanggan Prescription to IL-6 and TNF-α Contents in Rats with hepatic precancerous lesion

目的观察益脾养肝方对肝癌前病变大鼠血清白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平及肝功能的影响。方法将80只Wistar雄性大鼠随机分为空白组、模型组、益脾养肝方小剂量组、益脾养肝方大剂量组,每组20只。除空白组外,其余组均给予DENA(0.5 m L/100 g)腹腔注射,1次/84 h,50 mg/(kg·周),连续给药至16周;在此过程中,益脾养肝方小、大剂量组分别给予0.5 g/m L和1.0 g/m L益脾养肝方灌胃,空白组、模型组给予生理盐水灌胃,均1次/d。第16周灌胃24 h后处死大鼠,取血检测肝功能指标(ALT、AST、GGT)及IL-6、TNF-α水平,取肝组织进行HE染色观察。结果模型组ALT、AST、GGT、IL-6、TNF-α水平均明显高于空白组(P均<0.05);益脾养肝方小剂量组和益脾养肝方大剂量组ALT、AST、GGT、IL-6、TNF-α水平均明显低于模型组(P均<0.05),且益脾养肝方大剂量组各指标水平均明显低于小剂量组(P均<0.05)。肝组织HE染色显示,益脾养肝方小剂量组和益脾养肝方大剂量组大鼠肝脏病变明显轻于模型组。结论益脾养肝方可抑制肝癌前病变大鼠病情进展,可能是通过降低炎症因子IL-6和TNF-α的表达水平来实现的。

Objective It is to observe the influence of Yipi Yangganfang( YPYGF) on the expression of IL-6 and TNF-α in serum and hepatic function of rats with liver precancerous lesion. Methods 80 male Wistar rats were randomly divided into the blank control,model group,YPYGF small dose group and YPYGF large dose group,20 cases in each. Except for the blank group,the other groups were given intraperitoneal injection of DENA( 0. 5 mg/m L),1 times every 84 hours,50 mg/( kg·week),the drug was administered for 16 weeks. In the process,the animals in the YPYGF small dose group and the large dose group were given 0. 5 g/m L and 1. 0 g/m L YPYGF respectively,and the animals in the blank group and the model group were given normal saline for gastric perfusion,1 times per day. The rats were killed after sixteenth weeks of gastric perfusion for 24 hours,the indexes of liver function( ALT,AST,GGT) and the level of IL-6 and TNF-α were measured by blood sampling,the liver tissue was observed by HE staining. Results The levels of ALT,AST,GGT,IL-6 and TNF-α in the model group were significantly higher than those in the blank group( all P < 0. 05); the levels of ALT,AST,GGT,IL-6 and TNF-α in the YPYGF small and large dose groups were significantly lower than those in the model group( all P < 0. 05),and which in the YPYGF large dose group were significantly lower than those in the YPYGF small dose group( all P < 0. 05). HE staining of liver tissue showed that the liver lesions of rats in JPYGF small and large dose groups were significantly lighter than those in the model group. Conclusion YPYGF can inhibit the progression of liver precancerous lesions in rats,it may be achieved by reducing the expression level of inflammatory factors IL-6 and TNF-α.